About LILLY A/S
LILLY A/S is a Public Limited Company and was incorporated on May 29, 2006 in Denmark. Its corporate identification number is (CIN) 29606668 and its current status is Active.
Key Metrics
CIN
29606668
Current Status
Active
Entity Type
Public Limited Company
Date Of Incorporation
May 29, 2006
Contact Details for LILLY A/S
- Registered Address
- 2, Bugattivej, Vejle, 7100
Brands associated with LILLY A/S
There is one brand associated with LILLY A/S which include Lilly .
Name | Short Description | Founded Year | Location | Current Stage |
|---|---|---|---|---|
Developer of traditional pharmaceutical medicines | 1876 | Public |
Financials of LILLY A/S
Competitors & Alternates of LILLY A/S
Lilly is the only brand associated with LILLY A/S, and here are its Top 10 competitors ranked by Tracxn score:
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | AbbVie 2012, Chicago (United States), Public | Research-based biopharmaceutical company | $14.7B | 81/100 | |
2nd | Amgen 1980, Thousand Oaks (United States), Public | Developer of pharmaceutical products for treating multiple diseases | - | 81/100 | |
3rd | Gilead 1987, Foster City (United States), Acquired | Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | - | 80/100 | |
4th |  Johnson & Johnson 1886, New Brunswick (United States), Public | Manufacturer and supplier of beauty care products, medical devices, and pharmaceutical products | - | 76/100 | |
5th | Lilly 1876, Indianapolis (United States), Public | Developer of traditional pharmaceutical medicines | - | 75/100 | |
6th |  AstraZeneca 1999, Cambridge (United Kingdom), Public | Developer of pharmaceutical medicines for oncology and various chronic diseases | - | 73/100 | |
7th |  Regeneron Pharmaceuticals 1988, Tarrytown (United States), Public | Developer of antibodies for the treatment of cancer, eye diseases, inflammatory diseases & others | - | 71/100 | |
8th | Novartis 1996, Basel (Switzerland), Acquired | R&D focused on manufacturing of drugs for multiple therapeutic areas | - | 71/100 | |
9th |  Roivant Sciences 2014, New York City (United States), Public | Developer of therapeutics to treat neurology, oncology, rare, and endocrinology based diseases | $1.3B | 70/100 | |
10th |  Roche 1896, Basel (Switzerland), Public | Developer of pharmaceuticals and diagnostics kits | - | 70/100 |
News related to LILLY A/S
Media has covered brands linked with LILLY A/S for a total of 724 events in the last 1 year, 441 of them have been about company updates and 58 about partnerships.
•
Novo Nordisk sues Lilly for deceptive advertising in obesity drug battleExpansion•Jul 21, 2026•New Nordic, Lilly
•
•
Eli Lilly to Acquire AtaiBeckley for $2.8 Billion Plus CVRContract Pharma•Jul 16, 2026•AtaiBeckley, Lilly, Mindset Pharma, The Biotech Growth Trust
•
AdvanCell Closes Oversubscribed $315M Series D Round to Advance Prostate Cancer TherapyContract Pharma•Jul 15, 2026•Ally Bridge Group, AdvanCell, Fidelity Investments, Bain Capital Life Sciences and 2 others
•
EC Approves Erbitux Combination for First-Line Treatment of BRAF V600E-Mutant mCRCPharmaTimes•Jul 14, 2026•Lilly
•
Chai Discovery Raises $400M Series C, Valued at $3.8B, for AI-Designed AntibodiesSiliconAngle•Jul 14, 2026•Pfizer, Novartis, Chai Discovery, Lilly
•
Eli Lilly and Company to Present Alzheimer's Disease Research at AAIC 2026PR Newswire•Jul 09, 2026•Lilly
•
Alchemab Therapeutics Raises £25 Mn in Series A FundingStartup Rise EU•Jul 09, 2026•British Business Bank, Alchemab, SV Health Investors, RA Capital Management and 5 others
•
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Attribution:
Contains data used under the terms for the use of Danish public data
FAQs about LILLY A/S
Explore our recently published Legal Entities
